| 招商通知 | | --- | | 第三届全球手术机器人大会 | | 第二届全球医疗科技大会 | 2025年7月1日 ， 专 注胶囊内窥镜技术创新的医疗科技公司 CapsoVision, Inc.（纳斯达克代码：CV） ，宣布其 首次公开募股 （IPO） 定价为每股 5.00 美元，共发行 550 万股普通股，预计募资 约2750万美元（约合人民币2亿） 。 股票于 7 月 2 日在纳斯达克 资本市场开始交易。这次发行不仅是融资事件，更意味着这家专注胃肠道诊断创新的公司，正试图在全球医疗市场中占据更重要的位 置。 CapsoVision 的首席执行官 Dean Burns 在公司发布会上表示："从一开始，我们的目标就是让胶囊内窥镜不仅能看见，更能看全。今 天的 IPO，是让我们更接近这个愿景的重要一步。" # 市 场与竞 争环 境 全球胶囊内窥镜市场预计到 2030 年将达到 12 亿美元。推动这一市场发展的核心动力是人口老龄化、消化道疾病患病率上升，以及人 们对非侵入性检查方式的偏好。特别是在结直肠癌筛查领域，随着人们预防意识增强，非侵入式检测的需求愈加迫切。 然而，CapsoVision 面对的竞争也异 ...

Core Viewpoint - CapsoVision, Inc. has successfully completed its initial public offering (IPO) of 5,500,000 shares at a price of $5.00 per share, raising gross proceeds of $27.5 million before expenses [1][2]. Company Overview - CapsoVision is a commercial-stage medical technology company focused on advanced imaging and AI technologies for capsule endoscopy solutions [1][4]. - The flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that provides high-resolution visualization of the small bowel [4]. - The company is developing a pipeline product, CapsoCam Colon, aimed at non-invasive colon imaging and polyp detection, with plans to expand across multiple gastrointestinal indications [4]. IPO Details - The shares began trading on the Nasdaq Capital Market under the ticker symbol "CV" on July 2, 2025 [1]. - The underwriters have a 30-day option to purchase an additional 825,000 shares at the IPO price [1]. - The offering was managed by The Benchmark Company, LLC and Roth Capital Partners [2]. Regulatory Information - A registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission (SEC) on July 1, 2025, allowing the offering to proceed [3].

Core Points - CapsoVision, Inc. has announced the pricing of its initial public offering (IPO) of 5,500,000 shares at $5.00 per share, with trading expected to begin on July 2, 2025 [1] - The offering is projected to generate gross proceeds of approximately $27.5 million before deducting underwriting discounts and commissions [2] - The company has granted underwriters a 30-day option to purchase an additional 825,000 shares at the IPO price [2] Company Overview - CapsoVision is a commercial-stage medical technology company focused on advanced imaging and AI technologies for capsule endoscopy solutions [1][4] - The flagship product, CapsoCam Plus®, is a wire-free capsule endoscope that provides high-resolution visualization of the small bowel [4] - The upcoming product, CapsoCam Colon, aims to facilitate non-invasive colon imaging and polyp detection, with plans to expand across various gastrointestinal indications [4]

报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 近日， 美国胶囊内窥镜公司CapsoVision 向美国证券交易委员会（SEC）提交首次公开募股（IPO）申请， 计 划筹资最高3000万美元（约合2.2亿人民币） 。根据S-1文件，公司拟发行约250万股普通股，发行价格区间为 每股10至12美元，股票代码为"CAPS"，预计将登陆纳斯达克市场。 公司此次上市旨在强化其在非侵入性消化道诊断领域的布局。此次IPO预计将加快CapsoCam Plus的全球商业化 推进，并为下一代产品研发及全球供应链优化提供资金保障。 此次IPO募集资金将主要用于CapsoCam Plus产品的市场推广、下一代技术的研发、生产扩张及债务偿还，以增 强公司整体财务结构和市场竞争力。 # 产 品简介 CapsoVision的核心产品为 CapsoCam Plus ，是一款专用于小肠检查的可吞咽式胶囊内窥镜，提供非侵入性、 高图像质量的消化道检查手段。 产品自2016年获FDA 510(k)认证以来，已成为公司商业化主力， 并于2025年 获得用于2岁及以上儿童患者的适应症扩展， 进一步打开儿科诊断市场。 ...